These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 17826840)

  • 1. Small molecules affecting transcription in Friedreich ataxia.
    Gottesfeld JM
    Pharmacol Ther; 2007 Nov; 116(2):236-48. PubMed ID: 17826840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Friedreich ataxia: an update on animal models, frataxin function and therapies.
    González-Cabo P; Llorens JV; Palau F; Moltó MD
    Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.
    Gottesfeld JM
    Neurotherapeutics; 2019 Oct; 16(4):1032-1049. PubMed ID: 31317428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia.
    Evans-Galea MV; Lockhart PJ; Galea CA; Hannan AJ; Delatycki MB
    Discov Med; 2014 Jan; 17(91):25-35. PubMed ID: 24411698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.
    Al-Mahdawi S; Pinto RM; Varshney D; Lawrence L; Lowrie MB; Hughes S; Webster Z; Blake J; Cooper JM; King R; Pook MA
    Genomics; 2006 Nov; 88(5):580-90. PubMed ID: 16919418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures.
    Lai JI; Nachun D; Petrosyan L; Throesch B; Campau E; Gao F; Baldwin KK; Coppola G; Gottesfeld JM; Soragni E
    J Biol Chem; 2019 Feb; 294(6):1846-1859. PubMed ID: 30552117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia.
    Soragni E; Herman D; Dent SY; Gottesfeld JM; Wells RD; Napierala M
    Nucleic Acids Res; 2008 Nov; 36(19):6056-65. PubMed ID: 18820300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
    Marmolino D; Acquaviva F
    Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.
    Rai M; Soragni E; Chou CJ; Barnes G; Jones S; Rusche JR; Gottesfeld JM; Pandolfo M
    PLoS One; 2010 Jan; 5(1):e8825. PubMed ID: 20098685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivirus-meditated frataxin gene delivery reverses genome instability in Friedreich ataxia patient and mouse model fibroblasts.
    Khonsari H; Schneider M; Al-Mahdawi S; Chianea YG; Themis M; Parris C; Pook MA; Themis M
    Gene Ther; 2016 Dec; 23(12):846-856. PubMed ID: 27518705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich's Ataxia Gene During Somatic Cell Reprogramming.
    Polak U; Li Y; Butler JS; Napierala M
    Stem Cells Dev; 2016 Dec; 25(23):1788-1800. PubMed ID: 27615158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milestones in Friedreich ataxia: more than a century and still learning.
    Abrahão A; Pedroso JL; Braga-Neto P; Bor-Seng-Shu E; de Carvalho Aguiar P; Barsottini OG
    Neurogenetics; 2015 Jul; 16(3):151-60. PubMed ID: 25662948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered nucleosome positioning at the transcription start site and deficient transcriptional initiation in Friedreich ataxia.
    Chutake YK; Costello WN; Lam C; Bidichandani SI
    J Biol Chem; 2014 May; 289(22):15194-202. PubMed ID: 24737321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-based approaches toward Friedreich ataxia therapeutics.
    Hebert MD; Whittom AA
    Cell Mol Life Sci; 2007 Dec; 64(23):3034-43. PubMed ID: 17828464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Regulation of the Disease-Causing Gene
    Dong YN; Mercado-Ayón E; Coulman J; Flatley L; Ngaba LV; Adeshina MW; Lynch DR
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
    Herman D; Jenssen K; Burnett R; Soragni E; Perlman SL; Gottesfeld JM
    Nat Chem Biol; 2006 Oct; 2(10):551-8. PubMed ID: 16921367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell and gene therapy for Friedreich ataxia: progress to date.
    Evans-Galea MV; Pébay A; Dottori M; Corben LA; Ong SH; Lockhart PJ; Delatycki MB
    Hum Gene Ther; 2014 Aug; 25(8):684-93. PubMed ID: 24749505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiogical and therapeutic progress in Friedreich ataxia.
    Puccio H; Anheim M; Tranchant C
    Rev Neurol (Paris); 2014 May; 170(5):355-65. PubMed ID: 24792433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia.
    Greene E; Mahishi L; Entezam A; Kumari D; Usdin K
    Nucleic Acids Res; 2007; 35(10):3383-90. PubMed ID: 17478498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.
    Rai M; Soragni E; Jenssen K; Burnett R; Herman D; Coppola G; Geschwind DH; Gottesfeld JM; Pandolfo M
    PLoS One; 2008 Apr; 3(4):e1958. PubMed ID: 18463734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.